2021
Poster: TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome
Foss F, Ito T, Dwyer K, Herr F. Poster: TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s248. DOI: 10.1016/s2152-2650(21)01564-0.Peer-Reviewed Original ResearchTCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome
Foss F, Ito T, Dwyer K, Herr F. TCL-194: Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2021, 21: s412. DOI: 10.1016/s2152-2650(21)01926-1.Peer-Reviewed Original ResearchGrade 0Blood involvementSézary syndromeMycosis fungoidesB2 patientsLymphocyte countClinical responseSézary cellsGrade 1Refractory mycosis fungoidesSeverity of lymphopeniaAbsolute lymphocyte countSkin responseT lymphocyte populationsPredictors of responseIncidence of infectionAnti-CCR4 antibodyMechanism of actionAbsolute lymphocyteAdvanced diseaseClinical outcomesLymphocyte populationsInfections/infestationsMogamulizumabT cells
2006
Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox
Chin KM, Foss FM. Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox. Clinical Lymphoma Myeloma & Leukemia 2006, 7: 199-204. PMID: 17229335, DOI: 10.3816/clm.2006.n.059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCD4-Positive T-LymphocytesClinical Trials as TopicDiphtheria ToxinFemaleHumansInterleukin-2Interleukin-2 Receptor alpha SubunitLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesReceptors, Interleukin-2Recombinant Fusion ProteinsSkin NeoplasmsTreatment OutcomeConceptsCutaneous T-cell lymphomaAdvanced stage diseaseT-cell lymphomaDenileukin diftitoxMedian survivalBiologic correlatesAdvanced-stage cutaneous T-cell lymphomaResponse ratePhase III registration trialNumber of CD4Single-center seriesAbsolute lymphocyte countOverall response rateT cell populationsCourse of therapyLymphocyte countClinical responseLymphocyte populationsDisease progressionDiftitoxPatientsRegistration trialsHuman interleukinLactate dehydrogenaseSurvival